Your browser doesn't support javascript.
loading
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
Mecklai, Alicia; Subacius, Haris; Konstam, Marvin A; Gheorghiade, Mihai; Butler, Javed; Ambrosy, Andrew P; Katz, Stuart D.
Afiliação
  • Mecklai A; Weill Cornell Medical College, New York, New York; New York University School of Medicine, New York, New York.
  • Subacius H; Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Konstam MA; The CardioVascular Center of Tufts Medical Center and Tufts Medical Center, Boston, Massachusetts.
  • Gheorghiade M; Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Butler J; Stony Brook School of Medicine, Stony Brook, New York.
  • Ambrosy AP; Duke University Medical Center, Durham, North Carolina.
  • Katz SD; New York University School of Medicine, New York, New York. Electronic address: stuart.katz@nyumc.org.
JACC Heart Fail ; 4(7): 580-588, 2016 07.
Article em En | MEDLINE | ID: mdl-27039131
OBJECTIVES: The aim of this study was to characterize the association between decongestion therapy and 30-day outcomes in patients hospitalized for heart failure (HF). BACKGROUND: Loop diuretic agents are commonly prescribed for the treatment of symptomatic congestion in patients hospitalized for HF, but the association between loop diuretic agent dose response and post-discharge outcomes has not been well characterized. METHODS: Cox proportional hazards models were used to estimate the association among average loop diuretic agent dose, congestion status at discharge, and 30-day post-discharge all-cause mortality and HF rehospitalization in 3,037 subjects hospitalized with worsening HF enrolled in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) study. RESULTS: In univariate analysis, subjects exposed to high-dose diuretic agents (≥160 mg/day) had greater risk for the combined outcome than subjects exposed to low-dose diuretic agents (18.9% vs. 10.0%; hazard ratio: 2.00; 95% confidence interval: 1.64 to 2.46; p < 0.0001). After adjustment for pre-specified covariates of disease severity, the association between diuretic agent dose and outcomes was not significant (hazard ratio: 1.11; 95% confidence interval: 0.89 to 1.38; p = 0.35). Of the 3,011 subjects with clinical assessments of volume status, 2,063 (69%) had little or no congestion at hospital discharge. Congestion status at hospital discharge did not modify the association between diuretic agent exposure and the combined endpoint (p for interaction = 0.84). CONCLUSIONS: Short-term diuretic agent exposure during hospital treatment for worsening HF was not an independent predictor of 30-day all-cause mortality and HF rehospitalization in multivariate analysis. Congestion status at discharge did not modify the association between diuretic agent dose and clinical outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Readmissão do Paciente / Benzazepinas / Mortalidade / Inibidores de Simportadores de Cloreto de Sódio e Potássio / Antagonistas dos Receptores de Hormônios Antidiuréticos / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: JACC Heart Fail Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Readmissão do Paciente / Benzazepinas / Mortalidade / Inibidores de Simportadores de Cloreto de Sódio e Potássio / Antagonistas dos Receptores de Hormônios Antidiuréticos / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: JACC Heart Fail Ano de publicação: 2016 Tipo de documento: Article